TCGA-44-2662-01A-01R-A278-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.500
- MITOTIC_SPINDLE+0.450
- ANDROGEN_RESPONSE+0.370
- GLYCOLYSIS+0.370
- MTORC1_SIGNALING+0.360
- IL6_JAK_STAT3_SIGNALING+0.340
- G2M_CHECKPOINT+0.330
- HYPOXIA+0.330
- E2F_TARGETS+0.320
- INFLAMMATORY_RESPONSE+0.300
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.510
- KRAS_SIGNALING_DN-0.390
- APICAL_SURFACE-0.320
- ESTROGEN_RESPONSE_LATE-0.280
- MYOGENESIS-0.280
- WNT_BETA_CATENIN_SIGNALING-0.230
- HEDGEHOG_SIGNALING-0.180
- ESTROGEN_RESPONSE_EARLY-0.120
- COAGULATION-0.100
- INTERFERON_ALPHA_RESPONSE-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-2662-01A-01R-0946-07 | — | cohortA1 | 0.892 |
| 2 | TCGA-49-6743-01A-11R-1858-07 | — | cohortA4 | 0.850 |
| 3 | SRR934895 | — | — | 0.839 |
| 4 | SRR934746 | — | — | 0.813 |
| 5 | TCGA-86-7953-01A-11R-2187-07 | — | cohortA1 | 0.810 |
| 6 | SRR934942 | — | — | 0.797 |
| 7 | BS_0WQJP6ZG | Supratentorial Ependymoma | — | 0.792 |
| 8 | SRR934907 | — | — | 0.786 |
| 9 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.783 |
| 10 | SRR934778 | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |